Alembic Pharmaceuticals Limited announced its unaudited financial results for the quarter and nine months ended 31st December, 2025, showcasing steady growth across key financial metrics. The pharmaceutical company's Board of Directors approved the results at a meeting held on 5th February, 2026, along with a significant board appointment. The company has also fulfilled its regulatory obligations by publishing the results in leading newspapers on 6th February, 2026.

Financial Performance Overview

The company delivered robust performance in Q3FY26 with consolidated revenue from operations reaching Rs 1,876.31 crore, marking a 10.8% year-on-year growth from Rs 1,692.74 crore in Q3FY25. However, this represented a slight sequential decline from Rs 1,910.15 crore in Q2FY26.

Standalone Performance Highlights

The standalone financial results showed strong growth momentum with income from operations reaching Rs 1,642.24 crore in Q3FY26 compared to Rs 1,406.09 crore in the corresponding quarter of the previous year. Profit after tax on standalone basis stood at Rs 114.47 crore versus Rs 85.81 crore in Q3FY25.

Nine-Month Performance

For the nine-month period ended 31st December, 2025, the company demonstrated strong momentum with consolidated revenue of Rs 5,497.18 crore, representing a 12.1% increase from Rs 4,902.45 crore in the corresponding period of the previous year. Net profit for the nine-month period stood at Rs 472.07 crore compared to Rs 426.53 crore in the same period last year, reflecting a 10.7% growth.

Exceptional Items Impact

The company's Q3FY26 results were affected by an exceptional item of Rs 42.23 crore related to the implementation of new Labour Codes. On 21 November 2025, the Government of India notified provisions of Labour Codes that consolidate twenty-nine existing labour laws. This resulted in an incremental impact relating to gratuity and long-term compensated absences arising from the revised definition of wages.

Board Appointment and Regulatory Compliance

Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, liable to retire by rotation. His appointment will be effective from 1st April, 2026, upon completing his tenure as Executive Director on 31st March, 2026, subject to shareholder approval through postal ballot.

The company has complied with SEBI listing regulations by publishing extracts of its unaudited financial results in Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 6th February, 2026. Company Secretary Manisha Saraf submitted the intimation to both BSE and NSE regarding the newspaper publication.

Alembic Pharmaceuticals Limited has informed stock exchanges about the superannuation of Mr. Ashok Pandya, who served as Resident Director. The pharmaceutical company filed the mandatory disclosure on January 31st, 2026, notifying both BSE and NSE about this senior management change.

Management Transition Details

The company submitted the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events and information. The notification was signed by Company Secretary Manisha Saraf and includes detailed annexures as required by regulatory guidelines.

Superannuation Specifics

According to the regulatory filing, the management change occurred due to superannuation, with specific timing and procedural details outlined in the company's disclosure.

Regulatory Compliance

The disclosure demonstrates Alembic Pharmaceuticals' adherence to corporate governance requirements and transparency standards. The company provided comprehensive documentation including annexures as mandated by SEBI regulations for senior management personnel changes.

The notification was addressed to both major Indian stock exchanges where the company's shares are listed, ensuring complete regulatory compliance and stakeholder transparency regarding this organizational transition.